NCT01948908View on ClinicalTrials.gov

Volumes of Administration for Intranasal Midazolam

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Children Requiring Sedation to Facilitate Laceration Repair
Interventions
DRUG

Intranasal midazolam

Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).

Trial Locations (1)

10032

New York Presbyterian Morgan Stanley Children's Hospital, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT01948908 - Volumes of Administration for Intranasal Midazolam | Biotech Hunter | Biotech Hunter